About CorMedix
CorMedix is a company based in Bridgewater (United States) founded in 2006. CorMedix has raised $2.62 million across 3 funding rounds from investors including HHS. The company has 65 employees. CorMedix has completed 1 acquisition, including Melinta Therapeutics.
- Headquarter Bridgewater, United States
- Employees 65
- Stage Public
- SectorsHealthcare
- Website cormedix.com
- Social LinkedIn X
- Legal Name Cormedix Inc.
- Annual Revenue$311.71 M (USD)617.03as on Dec 31, 2025
- Net Profit$163.06 M (USD)0as on Dec 31, 2025
- EBITDA$165.13 M (USD)0as on Dec 31, 2025
- Total Equity Funding$2.62M (USD)
in 3 rounds
- Latest Funding Round$274.47K (USD), Grant
Aug 2017
- Investors
- Employee Count65
- Investments & Acquisitions
Funding Insights of CorMedix
CorMedix has successfully raised a total of $2.62M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $274.47 thousand completed in August 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2.62M
- Total Rounds 3
- Last Round Grant — $274,469
- First Round $2.62M
(Nov 2009)
- Investors Count 1
All 3 funding rounds of CorMedix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2017 | $274,469 | Grant | – | – | |
| Oct 2013 | $3M | Post-IPO | – | – | – |
| Nov 2009 | $2.62M | Seed | – | – | – |
1 investors in total: 1 institutional.
Investors in CorMedix
CorMedix has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - |
Investor details for CorMedix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of CorMedix
39 people are tracked at CorMedix (27 in leadership, 6 in board & advisors, 6 in team); the tracked headcount is 65.
| Name | Role | Group |
|---|---|---|
Peter Sullivan Pharmd | Senior Vice President, Market Access | Leadership |
Liz Masson-Hurlburt | EVP, Head of Clinical & Medical Affairs | Leadership |
Roman Rudinskiy | Director Of Analytics And Forecasting | Leadership |
Beth Zelnick Kaufman | Evp, Chief Legal Officer And Corporate Secretary | Leadership |
Susan Blum | Chief Financial Officer | Leadership |
Alex D. | VP Commercial Operations | Leadership |
Joseph L. | Director & Head, Drug Safety | Leadership |
Marga Pandey | Director Revenue & Government Pricing | Leadership |
Scott Abbott | Vice President, Head Of Marketing And Insights | Leadership |
Sibu Varghese | Vice President, Technical Operations | Leadership |
Tushar Mukherjee | Chief Manufacturing Officer | Leadership |
Donna E. Ucci | Svp, Head Of Global Quality | Leadership |
Jeanette MacCagnano | Senior Director, Quality Assurance, Regulatory And Audits | Leadership |
Vanessa Rivera | Director Quality Assurance & Regulatory Affairs | Leadership |
Katy Paturzo | Director, Quality Systems | Leadership |
Sandy Estrada | Senior Director- Medical Affairs Strategy | Leadership |
Mary Michaud | Senior Vice President Medical Affairs | Leadership |
Jason Butch | VP Finance & Accounting | Leadership |
Joe Todisco | CEO | Leadership |
Matt David | EVP & CFO | Leadership |
19 more people are available in the full profile.
Complete people profiles for CorMedix
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of CorMedix
CorMedix is a publicly listed company on the NASDAQ with ticker symbol CRMD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date25 Mar 2010
- Listed onNYSEAMERICAN: CRMD
- Listed entityCorMedix Inc.
- Exchange sectorHealth technology
- ISINUS21900C3088
- Share price$7.32 (+0.55% on the day) · 2026-10-08
- Market capitalisation$570.6M
- Price to earnings3.5
- EPS (diluted, trailing year)$2.10
- Volume (last session)1,018,410
Financials of CorMedix
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $311.7M | $163.1M | $165.1M |
| 2024 | $43.5M | -$17.9M | -$21.9M |
| 2023 | – | -$46.3M | -$48.8M |
| 2022 | $65,410 | -$29.7M | -$30.4M |
| 2021 | $190,940 | -$28.2M | -$29.3M |
Detailed financial statements for CorMedix
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CorMedix
CorMedix has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Melinta Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developer of bacterial ribosome-targeting drugs for MDR infections | melinta.com | Morristown, United States | 2000 | Aug 2025 | $300M |
Complete acquisition details for CorMedix
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of CorMedix
5 dated milestones of CorMedix across 19 years, from founding to its latest funding, stage changes and deals.
- Founded CorMedix is founded.
- Funding First funding round of $2.6M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Grant, of $274K.
- Acquisition Acquires Melinta Therapeutics.
Web traffic of CorMedix
The website of CorMedix (cormedix.com) receives about 9K visits a month.
- Monthly visits9K
▼ 8% vs previous month
Latest news on Cormedix
Complete news archive for CorMedix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to CorMedix
10 companies that operate in the same segment as CorMedix (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about CorMedix
CorMedix was founded in 2006 and raised its 1st funding round 3 years after it was founded.
CorMedix is headquartered in Bridgewater, United States. It is registered at Bridgewater, New Jersey, United States.
CorMedix is a funded company, having raised a total of $2.62M across 3 funding rounds to date. The company's 1st funding round was a Seed of $2.62M, raised on Nov 2009.
CorMedix has 65 employees.
Annual revenue of CorMedix is $311.71M as on Dec 31, 2025.
CorMedix was founded in 2006 as a biopharmaceutical company based in Bridgewater, United States. Therapeutic products are in-licensed, developed, and commercialized to address cardiac, renal, and infectious diseases. Operations center on Neutrolin, a solution designed to prevent infection, thrombosis, and biofilm in catheters for oncology, hemodialysis, and intensive care patients. CE approval has been obtained in Europe, with distribution planned for the United States, Middle East, South America, and Africa.
Yes, CorMedix is publicly traded on NASDAQ under the ticker symbol CRMD.
CorMedix has made 1 acquisition, including Melinta Therapeutics.
CorMedix has 1 investor. Key investors include HHS.
CorMedix operates through Cormedix Inc..